Takeda
Executive Director, CMC Regulatory Affairs
Sarah Pope Miksinski is currently an Executive Director in CMC Regulatory Affairs, at Takeda. Previously, she held positions at Gilead Sciences (July 2023 – September 2026) as Executive Director in CMC Regulatory Affairs, as both the Head of Policy, Advisory and Intelligence and the Head of Small Molecule Regulatory Affairs. She represents industry in various external capacities – including serving on PhRMA’s Global Quality and Manufacturing Committee, serving as chair of ISPE’s Regulatory Steering Council (2020-2025), and supporting multiple other advocacy efforts (review/inspection standards, nitrosamines, PDUFA, and KASA). In 2021, she was appointed as the PhRMA Topic Lead for ICH M4Q(R2) and served on the ISPE Board of Directors from 2022-2025.
Previously, Sarah served at AstraZeneca for over 5 years, holding roles in the CMC Regulatory Affairs space. Prior to that, she held a lengthy tenure at FDA, lasting from 2002-2018, where she and served as a primary, secondary and tertiary reviewer before being selected (2009) as a senior management official. She held multiple leadership roles in CDER’s Office of Pharmaceutical Quality, where she contributed heavily to many ongoing strategic and advocacy initiatives across the assessment and inspectional spaces.
Prior to joining FDA, she completed a postdoctoral fellowship at the National Institute of Health. She is trained as an organic chemist and possesses a PhD in organic chemistry (Oklahoma State University, 1999). She also has a B.A. in chemistry (Earlham College, 1994).